<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="229542">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00092339</url>
  </required_header>
  <id_info>
    <org_study_id>0966-190</org_study_id>
    <secondary_id>2004_069</secondary_id>
    <nct_id>NCT00092339</nct_id>
  </id_info>
  <brief_title>A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-190)(COMPLETED)</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Study to Evaluate the Effects of Rofecoxib 50 mg and Valdecoxib 40 mg in Patients With Postoperative Dental Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and effectiveness of two approved drugs
      in the treatment of pain following dental surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The duration of treatment is 1 day.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2002</start_date>
  <completion_date type="Actual">September 2002</completion_date>
  <primary_completion_date type="Actual">September 2002</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall analgesic effect as measured by total pain relief over 12 hours.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall analgesic effect over 8 hrs.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to onset of analgesic, peak analgesic and duration of analgesic effects.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of patients using and amount used of supplemental analgesia within 8, 12, and 24 hrs.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall safety and tolerability.</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Postoperative Pain</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK0966, rofecoxib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: valdecoxib, placebo</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Impaction of a molar tooth requiring removal

        Exclusion Criteria:

          -  Any known allergy to the study drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <reference>
    <citation>Daniels SE, Desjardins PJ, Bird SR, Smugar SS, Tershakovec AM. Rofecoxib 50 mg and valdecoxib 20 or 40 mg in adults and adolescents with postoperative pain after third molar extraction: results of two randomized, double-blind, placebo-controlled, single-dose studies. Clin Ther. 2006 Jul;28(7):1022-34.</citation>
    <PMID>16990080</PMID>
  </reference>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>September 15, 2015</lastchanged_date>
  <firstreceived_date>September 22, 2004</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dental surgery</keyword>
  <keyword>molar removal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Toothache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rofecoxib</mesh_term>
    <mesh_term>Valdecoxib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
